The Impact of Exacerbation Frequency on Clinical and Economic Outcomes in Swedish COPD Patients: The ARCTIC Study

被引:9
|
作者
Larsson, Kjell [1 ]
Janson, Christer [2 ]
Lisspers, Karin [3 ]
Stallberg, Bjorn [3 ]
Johansson, Gunnar [3 ]
Gutzwiller, Florian S. [4 ]
Mezzi, Karen [4 ]
Bjerregaard, Bine Kjoeller [5 ]
Jorgensen, Leif [5 ]
机构
[1] Karolinska Inst, Natl Inst Environm Med, Integrat Toxicol, SE-17177 Stockholm, Sweden
[2] Uppsala Univ, Dept Med Sci Resp Allergy & Sleep Res, Uppsala, Sweden
[3] Uppsala Univ, Dept Publ Hlth & Caring Sci, Family Med & Prevent Med, Uppsala, Sweden
[4] Novartis Pharma AG, Global Patient Access, Basel, Switzerland
[5] IQVIA Solut, Real World Evidence Solut, Copenhagen, Denmark
关键词
chronic obstructive pulmonary disease; exacerbations; mortality; lung function; healthcare cost; Sweden; OBSTRUCTIVE PULMONARY-DISEASE; MANAGEMENT; DIAGNOSIS; MORTALITY; OVERLAP; DECLINE;
D O I
10.2147/COPD.S297943
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: The aim of this study was to assess the association between exacerbation frequency and clinical and economic outcomes in patients with COPD. Patients and Methods: Electronic medical record data linked to National Health Registries were collected from COPD patients at 52 Swedish primary care centers (2000-2014). The outcomes analyzed were exacerbation rate, mortality, COPD treatments, lung function and healthcare costs during the follow-up period. Based on the exacerbation rate two years before index date, the patients were initially classified into three groups, either 0, 1 or >= 2 exacerbations per year. After the index date, the classification into exacerbation groups was updated each year based on the exacerbation rate during the last year of follow-up. A sensitivity analysis was conducted excluding patients with asthma diagnosis from the analysis. Results: In total 18,586 COPD patients were analyzed. A majority of the patients (60-70%) who either have had no exacerbation or frequent exacerbations (>= 2/year) during the preindex period remained in their group (ie, with 0 or >= 2 annual exacerbations) during up to 11 years of follow-up. Compared with having no exacerbation, mortality was higher in patients having 1 (HR; 2.06 [1.93-2.201) and >= 2 (4.58 [4.33-4.841) exacerbations at any time during the follow-up. Lung function decline was more rapid in patients with frequent exacerbations and there was an almost linear relationship between exacerbations frequency and mortality. Total healthcare costs were higher in the frequent exacerbation group (>= 2/year) than in patients with no or one exacerbation annually (p<0.0001 for both). The results did not differ from the main analysis after exclusion of patients with a concurrent asthma diagnosis. Conclusion: In addition to faster lung function decline and increased mortality, frequent exacerbations in COPD patients imply a significant economic burden.
引用
收藏
页码:701 / 713
页数:13
相关论文
共 50 条
  • [41] Clinical Impact of Multidisciplinary Outpatient Care on Outcomes of Patients with COPD
    Mansoor, Sahar
    Obaida, Zaid
    Ballowe, Lorna
    Campbell, Amanda R.
    Patrie, James T.
    Byrum, Timothy D.
    Shim, Yun M.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 33 - 42
  • [42] IMPACT OF ANEMIA ON MORTALITY OF PATIENTS WITH ACUTE COPD EXACERBATION
    Jhand, Aravdeep
    Munir, Ahmed
    Macaraeg, Jeffrey
    Walters, Ryan
    Millner, Paul
    Andukuri, Venkata
    CRITICAL CARE MEDICINE, 2019, 47
  • [43] Impact of diabetes in patients admitted with acute exacerbation of COPD
    Benson, Rosalind
    Kazmi, Nosheen
    Pocock, Anne
    Huq, Syed
    Agarwal, Sanjeev
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [44] OUTCOMES OF PATIENTS WITH OSA/COPD OVERLAP SYNDROME HOSPITALIZED FOR ACUTE COPD EXACERBATION
    Olanipekun, Titilope
    Igbinomwanhia, Efehi
    Olanipekun, Olalekan
    Okoli, Chimuanya
    Chris-Olaiya, Abimbola
    Sanchez-Nadales, Alejandro
    Westney, Gloria
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 481 - 481
  • [45] Exacerbation outcomes with LAMA/LABA and ICS/LABA in high risk COPD patients in the IMPACT trial
    Lipson, David A.
    Barnhart, Frank
    Boucot, Isabelle
    Crim, Courtney
    Brealey, Noushin
    Criner, Gerard J.
    Dransfield, Mark
    Halpin, David M. G.
    Kilbride, Sally
    Han, Meilan K.
    Lange, Peter
    Lomas, David A.
    Martinez, Fernando J.
    Singh, Dave
    Naya, Ian Naya
    Jones, Christine Elaine
    Wise, Robert
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [46] COPD patients admitted in ICU for acute exacerbation: Impact of exacerbation factors on prognosis
    Ben Mansour, Amani
    Merhabene, Takoua
    Jamoussi, Amira
    Ben Khlil, Jalila
    Besbes, Mohamed
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [47] Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study
    Suzuki, Masaru
    Makita, Hironi
    Ito, Yoichi M.
    Nagai, Katsura
    Konno, Satoshi
    Nishimura, Masaharu
    EUROPEAN RESPIRATORY JOURNAL, 2014, 43 (05) : 1289 - 1297
  • [48] Duration of noninvasive ventilation is not a predictor of clinical outcomes in patients with acute exacerbation of COPD and respiratory failure
    Ghazala, Laith
    Hatipoglu, Umur
    Devnani, Tanya
    Covert, Erin
    Hanks, Justin
    Edwards, Katelyn
    Macmurdo, Maeve
    Li, Manshi
    Wang, Xiaofeng
    Duggal, Abhijit
    CANADIAN JOURNAL OF RESPIRATORY THERAPY, 2021, 57 (01): : 113 - 118
  • [49] Clinical outcome of patients admited with acute exacerbation of COPD
    Vigg, A
    Vigg, A
    Vigg, A
    Mantri, S
    CHEST, 2005, 128 (04) : 256S - 256S
  • [50] DOES BLOOD EOSINOPHIL COUNT CORRELATE WITH CLINICAL OUTCOMES IN PATIENTS PRESENTING WITH AN INFECTIVE EXACERBATION OF COPD?
    Atkins, O.
    Kaushik, K.
    THORAX, 2018, 73 : A133 - A134